帕拉丁科技公司定价1580万美元公开募股，资助肥胖计划

2025-11-06 22:02

Palatin Technologies (OTC:PTNT) priced an underwritten public offering of 2.43M shares (or pre-funded warrants) at a combined price of $6.50/unit.
Each unit includes one share (or pre-funded warrant), one Series J Warrant, and one Series K Warrant, each to purchase one share.
Series J Warrants: exercisable at $6.50, expire 18 months after issuance or 31 days after FDA acceptance of Palatin’s obesity IND.
Series K Warrants: exercisable at $8.125, expire in five years, but terminate early if the corresponding Series J Warrants remain unexercised after the FDA period.
Gross proceeds expected at ~$15.8M, with a 45-day option for underwriters to buy 364,615 additional shares.
Closing expected November 12, 2025.
Proceeds will fund Palatin’s obesity drug development, along with working capital and general corporate purposes.

More on Palatin Technologies